RNA splicing antisense technology studied at Cold Spring Harbor Laboratory (CSHL) effectively corrected an mRNA splicing defect found in spinal muscular atrophy (SMA) patients, and is now ready to be tested in mouse models.
Almost 60 percent of pacemaker patients had undiagnosed sleep apnea — possibly contributing to their heart disease — researchers reported in a small study in Circulation: Journal of the American Heart Association.
Twelve institutions today were named by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), as HIV/AIDS clinical trial units (CTUs) for the Microbicide Trials Network (MTN), a new HIV/AIDS clinical trials network established by NIAID last year.
3M Health Care announced the launch of a new Medical Diagnostics business unit that will focus on developing and commercializing rapid diagnostic product solutions for the detection of key infectious pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and other treatment-resistant microbes.
Scientists hoping to find new treatments for one of the world?s most deadly infectious diseases say drugs used to treat common fungal infections may provide the answer.
Two new studies by University of California, Berkeley, scientists highlight the amazing promiscuity of genes, which appear to shuttle frequently between organisms, especially more primitive organisms, and often in packs.
Small amounts of alcohol can interfere with the growth of a fetus, but added cholesterol may help prevent a wide array of neurological and physical defects from alcohol exposure, according to a new study in laboratory fish.
A new study involving a type of stem cells from the lungs of transplant patients demonstrates for the first time that these progenitor cells reside in adult organs and are not derived from bone marrow, which leads to the possibility that the cells may be able to help with the rejection of donated organs and with various kinds of lung disease.
Cancer Treatment Centers of America announced today its plans to launch a new cancer vaccine therapy that expands treatment options for thousands of women with advanced stage ovarian cancer. This innovative treatment will be offered by Cancer Treatment Centers of America and developed by AVAX Technologies, Inc. (OTCMarket: AVXT.OB).
The first detailed images of an elusive drug target on the outer wall of bacteria may provide scientists with enough new information to aid design of novel antibiotics. The drugs are much needed to treat deadly infections initiated by Staphylococcus aureus and other bacterial pathogens.